FluoGuide A/S, a biotech company specializing in precision cancer surgery, has published its interim report for the period from January 1 to September 30, 2024. The report details the company's financial performance and updates on its clinical trials.
In the third quarter of 2024, FluoGuide focused on preparing for the FG001 phase II head and neck trial application (CT-005), incorporating feedback from global key opinion leaders regarding patient needs and trial design. This preparation follows the positive results from the earlier FG001 trial (CT-003), which demonstrated successful cancer detection in all 16 patients involved. Additionally, the company is making progress on clinical and regulatory plans for aggressive brain cancer, with updates anticipated in the first half of the next year.
Financially, FluoGuide reported no revenue for the period and a net loss of DKK 5,495 thousand for the third quarter, contributing to a total net loss of DKK 20,218 thousand for the first nine months of 2024. The company's total number of shares remained unchanged at 13,620,149 as of September 30, 2024.
Key highlights from the report include the appointment of Jens Ellrich as Chief Medical Officer and the submission of the Clinical Trial Application for the phase II trial in head and neck cancer (CT-005). Jens Ellrich commented on the significance of this milestone, emphasizing the extensive planning and positive interim results for FG001.
FluoGuide's lead product, FG001, aims to improve surgical accuracy by illuminating cancer cells intraoperatively, potentially reducing local recurrence rates and surgical complications. The company's technology platform also explores the use of photothermal therapy (PTT) for cancer treatment, offering a direct therapeutic effect while sparing healthy tissue.
For more information about FluoGuide's pipeline, technology, and upcoming events, visit www.fluoguide.com.
